Killian Meara

Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.

Cytokine signaling pathways in sera from underrepresented minority patients were found to be enriched.

A survey found that only 24.6% of respondents have conducted a skin self-examination in the past 2 months.

A survey shows cancer centers are struggling, Google expands its generative AI into health care, and the WHO announces enhanced collaboration with the Global Fund.

Cue Health gets FDA’s first de novo approval for at-home COVID-19 test, Novavax says its new vaccine will fight new variants and HHS creates new cert standards for peer support workers.

With the rise of prescription digital therapeutics, pharmacists will need to prepare to manage the new paradigms of care.

Merck sues the federal government, the FDA will allow cancer drug imports from China, and a drug from GSK shows promise for endometrial cancer treatment.

Mandy Cohen is set to become the next CDC director, Medicare will cover a new class of Alzheimer’s drugs, and the WHO announces a landmark digital health initiative.

New research suggests that chronotropic incompetence contributes to exercise limitations in Long COVID.

Patients using the treatment reported reduced headache intensity and better quality of life.

Free medicine distribution was linked with a lower median total health care spending of $1641 per year over a 3-year period.

A majority of patients say that taking cannabis helps them with chronic pain management and other conditions.

A short supply of cisplatin and carboplatin is forcing health care providers to find less effective alternative treatments.

Active tobacco use and BMI were inversely related to the risk of developing IPD.

Exhaled carbon monoxide in vape users significantly decreased between their first and third clinical visits.

Some patients with PAH need to travel long distances, which may impact their access to quality care providers.

A higher dose of the carbonic anhydrase inhibitor does not seem to provide any additional improvements.

Balanced products showed greater improvements compared to either CBD-dominant or THC-dominant products.

A new meta-analysis found duloxetine to be the only commonly prescribed medication that was effective.

Insulet plans to commercialize the new product in the United States starting in 2024.